

## Peer Review File

Article information: <https://dx.doi.org/10.21037/ccco-23-118>

### Review comments

**I will only make a very brief comment because time is precious and I have other pressing matters to attend to.**

**Comment 1: We have recently had accepted for publication in the BMJ an article in which we comment on (Iyengar, Boike, and al 2023) and other practice guidelines on this topic. I will supply a pre-print which is yet to undergo final editing and cannot be cited. However, I share it as it is relevant to the article by Sergio Martinez-Recio, Andres Barba, Nuria Farré, Margarita Majem. We are much more critical than they are.**

**-Reply 1:** We thank the reviewer for providing the preprint of his recently accepted manuscript, as well as his opinion and experience in the field. We can't wait to see this article published and suitable for sharing and commenting. This preprint expresses concern about the relevance of providing local therapy to lung metastases derived from primary colorectal cancer. However, the guideline commented in our editorial commentary refers to treatment of oligometastatic disease from non-small cell lung cancer in any organ, which is not exactly the same scenario. Providing local therapy in oligometastatic NSCLC has shown to improve survival (References 10-13). Of note, as a result of this comment we have added a mention to the reviewer's concern that favorable outcomes in oligometastatic disease may be explained by more indolent biology. We fully agree with the reviewer's other concerns expressed in the preprint that are already addressed in our editorial commentary, such as the need for shared decision-making with patients in clinical areas with weaker evidence, and the need to seek equity between higher and lower income countries.

**-Changes in the text:** We have added a sentence at the end of the Page 1, Paragraph 2, to address this comment: [“However, others believe that a more indolent biology \(rather than local treatments\) could explain the more favorable results observed”](#).

**The notion that there is a curable oligometastatic state (Hellman and Weichselbaum 1995) has been questioned (Treasure 2012) and the question remains unrefuted. I will also provide that paper.**

**-Reply:** We thank the reviewer for providing further documentation of the question of whether if oligometastatic disease can be cured. As a response to this comment, we have added this reference to our manuscript

**-Changes in the text:** We have added another sentence at the end of the Page 1, Paragraph 2, along with the reference provided for the reviewer. [“It has also been questioned whether the oligometastatic state can be cured \(citation\)”](#).

**Your first three references are of course part of the history of medicine being 24-28 years old. The registry (Pastorino et al. 1997) is a landmark but it is cautiously written and deserves to be read again if you want to cite it.**

**-Reply:** We agree with the reviewer that these references are part of the history but this is the reason why we think that they are really helpful to contextualize the subject addressed, which it is necessary in an editorial commentary. We are glad to see that the reviewer has also cited some of these articles in the attached pre-print. We have reviewed the registry by Pastorino et al to make sure that maintaining the reference is pertinent.

**-Changes in the text:** No changes have been done to the text in response to this comment.

**L.14 “Curation” is defined as the act or an instance of selecting and organizing artistic works for presentation in an exhibit, show, etc. [Webster] Example: the careful curation that went into the exhibit. Curation is done by a curator. The word you intend is “cure”. Cure is rarely achieved by removing or ablating metastases.**

**-Reply:** We appreciate this comment and we agree with the reviewer. As suggested, we have replaced the term “curation” with the word cure.

**-Changes in the text:** Page 1, Paragraph 1: “curation” has been replaced by “cure”.

Hellman, S., and R.R. Weichselbaum. 1995. "Oligometastases." J Clin. Oncol 13 (1): 8-10. <http://www.ncbi.nlm.nih.gov/pubmed/7799047>.

Iyengar, P., T Boike, and et al. 2023. "Treatment of Oligometastatic Non-Small Cell Lung Cancer: An ASTRO/ESTRO Clinical Practice Guideline." Practical Radiation Oncology.

Pastorino, U, M Buyse, G Friedel, Ginsberg RJ, P. Girard, P. Goldstraw, M Johnston, P. McCormack, and J.B. Putnam. 1997. "Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases." J Thorac Cardiovasc. Surg 113: 37-49.

Treasure, T. 2012. "Oligometastatic cancer: an entity, a useful concept, or a therapeutic opportunity?" J R. Soc. Med 105 (6): 242-246. <http://www.ncbi.nlm.nih.gov/pubmed/22722968>.